Facilitating drug development using full-length transmembrane protein platforms
A crucial step in preclinical drug development is the confirmation of the specific binding of the new therapeutic molecule to the target protein. Transmembrane proteins (TPs) such as ion channels, transporters or receptors provide many targets for cancer and other diseases. They are complex, making the production of those proteins in adequate amounts much more … Read more
